Pfizer announced April 7th a voluntary withdrawal of Bextra from the U.S. market due to safety concerns. Bextra is a prescription cox-2 selective, non-steroidal anti-inflammatory drug (NSAID) that was approved by the Food and Drug Administration (FDA) in November 2001 for the relief of joint pain from osteoarthritis, for the management of acute pain in adults, and for the treatment of menstrual symptoms. It is also approved for the relief of the signs and symptoms of rheumatoid arthritis in ...MORE